These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20042100)

  • 41. Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice.
    Coelho CH; Gazzinelli-Guimaraes PH; Howard J; Barnafo E; Alani NAH; Muratova O; McCormack A; Kelnhofer E; Urban JF; Narum DL; Anderson C; Langhorne J; Nutman TB; Duffy PE
    Vaccine; 2019 Feb; 37(8):1038-1045. PubMed ID: 30685251
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunoglobulin G antibodies to merozoite surface antigens are associated with recovery from chloroquine-resistant Plasmodium falciparum in Gambian children.
    Pinder M; Sutherland CJ; Sisay-Joof F; Ismaili J; McCall MB; Ord R; Hallett R; Holder AA; Milligan P
    Infect Immun; 2006 May; 74(5):2887-93. PubMed ID: 16622227
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential ability of specific regions of Plasmodium falciparum sexual-stage antigen, Pfs230, to induce malaria transmission-blocking immunity.
    Bustamante PJ; Woodruff DC; Oh J; Keister DB; Muratova O; Williamson KC
    Parasite Immunol; 2000 Aug; 22(8):373-80. PubMed ID: 10972844
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preclinical efficacy and immunogenicity assessment to show that a chimeric Plasmodium falciparum UB05-09 antigen could be a malaria vaccine candidate.
    Dinga JN; Gamua SD; Ghogomu SM; Titanji VPK
    Parasite Immunol; 2018 Mar; 40(3):. PubMed ID: 29284177
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antigenicity of a Bacterially Expressed Triple Chimeric Antigen of Plasmodium falciparum AARP, MSP-311 and MSP-119: PfAMSP-Fu35.
    Kalra A; Edula JR; Gupta PK; Pandey AK; Chauhan VS
    PLoS One; 2016; 11(10):e0165720. PubMed ID: 27798691
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mice immunised with synthetic peptide from N-terminal conserved region of merozoite surface antigen-2 of human malaria parasite Plasmodium falciparum can control infection induced by Plasmodium yoelii yoelii 265BY strain.
    Lougovskoi AA; Okoyeh NJ; Chauhan VS
    Vaccine; 1999 Dec; 18(9-10):920-30. PubMed ID: 10580206
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In immunization with Plasmodium falciparum apical membrane antigen 1, the specificity of antibodies depends on the species immunized.
    Miura K; Zhou H; Muratova OV; Orcutt AC; Giersing B; Miller LH; Long CA
    Infect Immun; 2007 Dec; 75(12):5827-36. PubMed ID: 17923516
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates.
    Flueck C; Frank G; Smith T; Jafarshad A; Nebie I; Sirima SB; Olugbile S; Alonso P; Tanner M; Druilhe P; Felger I; Corradin G
    Vaccine; 2009 May; 27(20):2653-61. PubMed ID: 19428875
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort.
    Adamou R; Dechavanne C; Sadissou I; d'Almeida T; Bouraima A; Sonon P; Amoussa R; Cottrell G; Le Port A; Theisen M; Remarque EJ; Longacre S; Moutairou K; Massougbodji A; Luty AJF; Nuel G; Migot-Nabias F; Sanni A; Garcia A; Milet J; Courtin D
    Malar J; 2019 Jun; 18(1):194. PubMed ID: 31185998
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
    Singh SK; Thrane S; Janitzek CM; Nielsen MA; Theander TG; Theisen M; Salanti A; Sander AF
    Vaccine; 2017 Jun; 35(30):3726-3732. PubMed ID: 28578824
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
    Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
    Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite Plasmodium falciparum.
    Woehlbier U; Epp C; Kauth CW; Lutz R; Long CA; Coulibaly B; Kouyaté B; Arevalo-Herrera M; Herrera S; Bujard H
    Infect Immun; 2006 Feb; 74(2):1313-22. PubMed ID: 16428781
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
    Arakawa T; Komesu A; Otsuki H; Sattabongkot J; Udomsangpetch R; Matsumoto Y; Tsuji N; Wu Y; Torii M; Tsuboi T
    Infect Immun; 2005 Nov; 73(11):7375-80. PubMed ID: 16239536
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alga-produced malaria transmission-blocking vaccine candidate Pfs25 formulated with a human use-compatible potent adjuvant induces high-affinity antibodies that block Plasmodium falciparum infection of mosquitoes.
    Patra KP; Li F; Carter D; Gregory JA; Baga S; Reed SG; Mayfield SP; Vinetz JM
    Infect Immun; 2015 May; 83(5):1799-808. PubMed ID: 25690099
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunogenicity of dimorphic and C-terminal fragments of Plasmodium falciparum MSP2 formulated with different adjuvants in mice.
    Balam S; Jafarshad A; Servis C; Frank G; Reed S; Pink R; Druilhe P; Spertini F; Corradin G
    Vaccine; 2016 Mar; 34(13):1566-1574. PubMed ID: 26874325
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Plasmodium falciparum: further characterization of a functionally active region of the merozoite invasion ligand EBA-175.
    Sim BK; Carter JM; Deal CD; Holland C; Haynes JD; Gross M
    Exp Parasitol; 1994 May; 78(3):259-68. PubMed ID: 7512929
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of a Plasmodium-Specific Carrier Protein To Enhance Production of Recombinant
    Parzych EM; Miura K; Ramanathan A; Long CA; Burns JM
    Infect Immun; 2018 Jan; 86(1):. PubMed ID: 28993460
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relationship of antibodies to soluble Plasmodium falciparum antigen (Pf70) and protection against malaria in a human population living under intense transmission in Kinshasa, Zaire.
    Tshefu K; James MA
    Trop Med Parasitol; 1995 Jun; 46(2):72-6. PubMed ID: 8525288
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults.
    Hu J; Chen Z; Gu J; Wan M; Shen Q; Kieny MP; He J; Li Z; Zhang Q; Reed ZH; Zhu Y; Li W; Cao Y; Qu L; Cao Z; Wang Q; Liu H; Pan X; Huang X; Zhang D; Xue X; Pan W
    PLoS One; 2008 Apr; 3(4):e1952. PubMed ID: 18398475
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Allele-specific antibodies to Plasmodium falciparum merozoite surface protein-2 and protection against clinical malaria.
    Osier FH; Murungi LM; Fegan G; Tuju J; Tetteh KK; Bull PC; Conway DJ; Marsh K
    Parasite Immunol; 2010 Mar; 32(3):193-201. PubMed ID: 20398182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.